Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

--Vigil Neuroscience, Inc., a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi, today announced that ...

Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...

News GlobeNewswire Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference ...

Net Loss: Loss from operations for the third quarter ended September 30, 2023, were $20.5 million, compared to $17.5 million for the same period in 2022. About Vigil Neuroscience ...

Net Loss: Net loss from operations for the first quarter ended March 31, 2025 were $22.4 million, compared to $19.9 million for the same period in 2024. About Vigil Neuroscience ...

Vigil’s highly active, selective, and brain-penetrant small molecule TREM2 agonist, VG-3927, is designed to act as a molecular glue that potentiates the TREM2 signaling response to natural ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy. Read why VIGL is a Hold.

Vigil Neuroscience, Inc. (VIGL) closed the last trading session at $7.88, gaining 225.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...